Takeda Pharmaceutical

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food and Drug Administration (FDA) has approved EXKIVITY (mobocertinib) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemo

Takeda's EXKIVITY™ (mobocertinib) Approved by U.S. FDA as the First Oral Therapy Specifically Designed for Patients with EGFR Exon20 Insertion+ NSCLC

Takeda Pharmaceutical Co, which distributes Moderna Inc's COVID-19 shots in Japan, expects vaccines to become a bigger part of its portfolio as shots for dengue fever and COVID-19 near regulatory approval, its chief executive said.

Takeda eyes vaccine business growth as dengue, COVID-19 shots progress - CEO

Takeda's (TAK) pipeline candidate, pevonedistat, fails to achieve statistically significant event-free survival in patients with hematological disorders.

Takeda (TAK) Hematology Candidate Fails in Late-Stage Study

Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced topline data from the Phase 3 PANTHER study evaluating pevonedistat in blood cancer indications. The trial did not achieve the pre-defined statistical significance for the primary endpoint of event-free survival (EFS).

Takeda's Breakthrough Blood Cancer Drug Flunks In Phase 3 Study

Boston Beer Company

UP Fintech Holding

Even with the S&P 500 30% overvalued, incredible blue-chip bargains are still available. Today analysts believe that SAM, TIGR, and TAK could soar 52% to 164% in the next year alone.

3 Blue-Chips With 52%-164% Upside According To Wall Street

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the Phase 3 PANTHER (Pevonedistat-3001) study did not achieve pre-defined statistical significance for the primary endpoint of event-free survival (EFS). The trial evaluated whether the combination of pevonedistat plus azacitidine as first-line treatment for patients with higher-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) an

Takeda Provides Update on Phase 3 PANTHER (Pevonedistat-3001) Trial

Exelixis

Exelixis Inc's (NASDAQ: EXEL) collaborating partner Takeda Pharmaceutical Co Ltd (NYSE: TAK) and Ono Pharmaceutical Co Ltd have received approval for Cabometyx (cabozantinib) in Japan. The approval covers Cabometyx combined with Bristol-Myers Squibb Co's (NYSE: BMY) Opdivi (nivolumab) for unresectable or metastatic renal cell carcinoma (RCC).

Exelixis - Takeda's Cabometyx Scores Approval In Japan For Kidney Cancer

Takeda: A Pharmaceutical Gem From Japan

Preferred Apartment Communities

Bassett Furniture

Cathay General Bancorp

APTS, TAK, CATY, and BSET made it to the Zacks Rank #1 (Strong Buy) income stocks list on August 19, 2021

Top Ranked Income Stocks to Buy for August 19th

TUKWILA, Wash.--(BUSINESS WIRE)--BioLife Plasma Services Opens First All-Electric Plasma Donation Center

BioLife Plasma Services Opens First All-Electric Plasma Donation Center

Bunge Global SA

Weyerhaeuser

The following stocks could be of interest to growth-oriented investors since they represent equities in businesses whose price-earnings ratios are below 20, while their trailing 12-month earnings per share improved significantly over the past year.

3 Stock Picks for Growth-Oriented Investors

Finch Therapeutics Group Inc (NASDAQ: FNCH) announced that Takeda Pharmaceutical Company Limited (NYSE: TAK) has elected to take the lead on the development of FIN-524, now known as TAK-524, in ulcerative colitis. When Takeda teamed up with Finch Therapeutics in 2017 on inflammatory bowel disease (IBD), it planned to pick up programs after they'd finished Phase 2 trials.

Takeda To Lead Finch-Partnered Microbiome IBD Drug

Brandywine Realty

Donegal Group

F.N.B. Corp.

FS KKR Capital Corp

Golub Capital BDC

Kenon Hlds

Bank of N.T. Butterfield & Son

Northwest Bancshares

Oaktree Specialty Lending

Owl Rock Capital Corp

People's United Financial

Qiwi

Rio Tinto plc Sponsored

United Bankshares

Universal Corp

Vale S.A.

"Benjamin Graham Value Stocks match the criteria Benjamin Graham followed." - YCharts Value Screener.

27 Ideal Dividends To Buy Now Per Ben Graham's Formula

What if I told you there was a blue chip that was offering a safe 5% yield yet was 45% undervalued? Here are the three reasons why Takeda Pharma might be just the thing you need to enjoy generous yield today and a rich retirement tomorrow.

5%-Yielding Takeda Pharma Could Triple In 5 Years

OSAKA, Japan--(BUSINESS WIRE)--Final Results from the Phase 3 HELP Study™ Open-Label Extension - the longest study conducted to date in patients with HAE - in the journal Allergy

Final Results from the Longest Hereditary Angioedema Study of Active Treatment Duration Conducted to Date Support the Sustained Safety and Efficacy of TAKHZYRO® (lanadelumab) Injection for Long-Term Prevention of Hereditary Angioedema Attacks

AbbVie

Bristol-Myers

Merck

It has become the proverbial broken record. Every time it seems like yields on government securities will start trending higher, they roll over again.

4 Big Pharma Dividend Stocks to Buy as Yields Near 2021 Lows

Takeda Pharmaceutical reported its fiscal Q1 result highlighted by strong trends across its core global drug brands. The company has an extensive pipeline of drug candidates with the potential for 5 regulatory approvals over the next year.

Takeda Pharmaceutical: 5% Dividend Yield With Bullish Catalysts This Year

Takeda Pharmaceutical Co said on Monday it will record a provision of about 63 billion yen ($574.56 million) in its financial statements for the first quarter to reflect a decision by Ireland's tax appeals body relating to tax assessment received by company's unit on a break fee.

Takeda to record 63 billion yen provision, update Q1 results on Irish tax issue

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the receipt of a decision by the Irish Tax Appeals Commission on July 30, 2021 (IST) to uphold the Irish Revenue Commissioners' position related to the treatment of a break fee received by Shire plc (“Shire”) in October 2014 from AbbVie Inc. (“AbbVie”). Shire was acquired by Takeda in January 2019. Takeda intends to challenge this outcome through all available legal means includin

Takeda Receives Decision by the Irish Tax Appeals Commission Relating to Tax Assessment on Break Fee Shire Received from AbbVie

Weber

Takeda Pharmaceutical Co Ltd (TAK) CEO Christophe Weber on Q1 2022 Results - Earnings Call Transcript

Takeda Will Focus its Efforts on Dengue, Zika and Pandemic Vaccines Takeda Will Focus its Efforts on Dengue, Zika and Pandemic Vaccines

Takeda and Frazier Healthcare Partners Announce Collaboration to Launch HilleVax, Inc. to Develop Clinical Stage Norovirus Vaccine Candidate

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) today announced financial results for the first quarter of fiscal year 2021 (period ended June 30, 2021). Based on the solid first-quarter results, the Company also confirmed its fiscal year 2021 management guidance and forecast. Fiscal year 2021 remains a year of inflection with Takeda positioned for topline acceleration and continued pipeline progress, including critical regulatory submission

Takeda Delivers Solid First Quarter FY2021 Results, Positioning Company to Accelerate Topline Growth and Continued Pipeline Progress

The FDA has granted Breakthrough Therapy Designation to Takeda Pharmaceutical Company Limited's (NYSE: TAK) TAK-994 for excessive daytime sleepiness (EDS) in patients with narcolepsy type 1 (NT1). The oral orexin agonist is currently in Phase 2 study.

Takeda's Narcolepsy Candidate Gets FDA Breakthrough Therapy Tag

CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to TAK-994,1 its Phase 2 investigational oral orexin agonist, which is designed to selectively target orexin 2 receptors. TAK-994 is currently being studied for the treatment of excessive daytime sleepiness (EDS) in patients with narcolepsy type 1 (NT1),2 a chronic ne

U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to Takeda's Investigational Compound, TAK-994, an Oral Orexin Agonist in Clinical Development for Narcolepsy Type 1 (NT1)

OSAKA, Japan--(BUSINESS WIRE)--Takeda Data at ISTH 2021 Highlight the Benefits of Prophylaxis for Patients with Rare Bleeding Disorders

Takeda Data at ISTH 2021 Highlight the Benefits of Prophylaxis for Patients with Rare Bleeding Disorders

News for Takeda Pharmaceutical Stock (TAK)